Navigation Links
Is prenatal screening for rare diseases like spinal muscular atrophy too costly?
Date:3/8/2010

New York, NY, March 8, 2010 Spinal Muscular Atrophy (SMA) is one of many serious disorders for which prenatal testing is available. SMA affects approximately 1 in 10,000 live births and is the leading genetic cause of infant mortality and the second most common autosomal recessive disorder, after cystic fibrosis. Although the American College of Medical Genetics recommends carrier testing for all couples, the American College of Obstetricians and Gynecologists has issued a recommendation to the contrary, citing lack of information about the costs and benefits of screening for SMA. An article which may shed light on this controversy appears in the March 2010 issue of the American Journal of Obstetrics & Gynecology.

Using a decision analytic model, the authors found that 12,500 women need to be screened to prevent one case of SMA, at a cost of $5 million per case averted. They also determined that at $4.9 million per Quality-Adjusted Life Year (QALY), such screening was not cost-effective. Maternal QALY was used to measure the combined effects of caring for a child who suffers from the disease with resultant premature death and disability.

The cost of the procedures involved, maternal and paternal genetic testing, fetal amniocentesis and genetic testing of fetal cells, were all estimated from data published in the literature. The model assumed that couples with a positive fetal test would elect pregnancy termination. Lifetime costs of caring for an affected child were estimated from costs for similar diseases documented in the medical literature. All costs were adjusted to 2009 dollars using the Consumer Price Index.

The authors found that the cost per case averted was the most influenced by the baseline prevalence of disease in the population screened. For those couples with a higher prevalence, such as those with a family history of disease, screening may be a cost-effective strategy.

Writing in the article, Sarah E. Little, MD, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, and co-authors state that "our estimated cost per added QALY falls far beyond what is usually considered to be cost effective. SMA screening does not approach the cost-effective range ($50-100,000/QALY) until the cost of severe disease is over $7 million or the cost of the mild disease is over $17 million, both of which are more than 20 times the baseline estimates. As such, we feel there is little chance that the basic finding that universal SMA testing is not cost effective would change appreciably with different model inputs."


'/>"/>

Contact: Pamela Poppalardo
ajogmedia@elsevier.com
732-238-3628
Elsevier Health Sciences
Source:Eurekalert

Related biology news :

1. MIT: Prenatal arsenic exposure detected in newborns
2. Trainor Lab characterizes gene essential for prenatal development of nervous system
3. Moderate prenatal exposure to alcohol and stress in monkeys can cause touch sensitivity
4. Low sperm count may be associated with prenatal testosterone excess
5. Microarray analysis improves prenatal diagnosis
6. Prenatal meth exposure linked to abnormal brain development
7. How to deliver the news? New advice for doctors diagnosing prenatal Down syndrome
8. Sex-based prenatal brain differences found
9. Good parenting triumphs over prenatal stress
10. UNC study questions FDA genetic-screening guidelines for cancer drug
11. MIT: Micro livers could aid drug screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
Breaking Biology News(10 mins):
(Date:6/27/2017)... ... ... According to a recent report from the Environmental Security ... short- or long-term effects on benthic communities. , The ESTCP evaluated the ... Puget Sound Naval Shipyard & Intermediate Maintenance Facility in Bremerton, Washing. Data was ...
(Date:6/27/2017)... Iowa (PRWEB) , ... June 27, 2017 , ... ... technology license agreement whereby DuPont gains exclusive rights to the ERS patent portfolio ... ERS was formed to commercialize the foundational intellectual property (IP) of the CRISPR-Cas ...
(Date:6/26/2017)... Milwaukee, WI (PRWEB) , ... June 26, 2017 , ... ... today in role of Sales Director, focused on leading new business development and ensuring ... 10 years of experience in the food ingredient industry in technical, marketing and sales ...
(Date:6/26/2017)... ... June 26, 2017 , ... Two new members were elected to the ... 9, 2017: Jeremy Nowak, President, J Nowak Strategy and Michele Masucci, Ph.D., Vice President ... of Glen N. Gaulton and Kenneth L. Kring, and re-election of David P. Holveck ...
Breaking Biology Technology: